Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.00% $1.230
America/New_York / 22 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 19.33 mill |
EPS: | -7.58 |
P/E: | -0.160 |
Earnings Date: | May 06, 2024 |
SharesOutstanding: | 15.72 mill |
Avg Daily Volume: | 0.0956 mill |
RATING 2024-04-22 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Neutral | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.160 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.03x |
Company: PE -0.160 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.213 (-1.37%) $-0.0168 |
Date: 2024-04-23 |
Expected Trading Range (DAY) |
---|
$ 1.087 - 1.373 ( +/- 11.63%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-05 | Payne Fletcher | Buy | 55 000 | Employee Stock Option (Right to Buy) |
2024-02-05 | Bejar Rafael | Buy | 35 000 | Employee Stock Option (Right to Buy) |
2024-02-05 | Ledru Philippe | Buy | 11 000 | Employee Stock Option (Right to Buy) |
2024-02-05 | Rice William G. | Buy | 70 000 | Employee Stock Option (Right to Buy) |
2024-02-05 | Seizinger Bernd R. | Buy | 3 333 | Director Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 94 transactions |
Buy: 9 955 760 | Sell: 550 471 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.230 (0.00% ) |
Volume | 0.0119 mill |
Avg. Vol. | 0.0956 mill |
% of Avg. Vol | 12.49 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.